Nasdaq

American Medical Association Grants PLA Code to Tempus Algorithmic Test, PurISTSM

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the company’s PurISTSM algorithmic test has received a ...
Nasdaq

Tempus AI reports clinical launch of IPS algorithmic test

Tempus AI (TEM) announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a ...
Yahoo Finance

Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

CHICAGO, January 27, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study ...
Business Wire

Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has ...